vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and THOMSON REUTERS CORP (TRI). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $1.8B, roughly 1.6× THOMSON REUTERS CORP). THOMSON REUTERS CORP runs the higher net margin — 17.5% vs -3.7%, a 21.2% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs 2.6%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
The second and current incarnation of News Corporation, doing business as News Corp, is an American mass media and publishing company headquartered at 1211 Avenue of the Americas in Midtown Manhattan, New York City. The company was formed on June 28, 2013, as a spin-off of the first News Corporation, whose legal successor was 21st Century Fox, which held its media and entertainment assets. Operating across digital real estate information, news media, book publishing, and cable television, New...
BHC vs TRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $1.8B |
| Net Profit | $-103.0M | $313.0M |
| Gross Margin | — | — |
| Operating Margin | 17.0% | 24.4% |
| Net Margin | -3.7% | 17.5% |
| Revenue YoY | 9.3% | 2.6% |
| Net Profit YoY | -205.1% | -62.8% |
| EPS (diluted) | $-0.30 | $0.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.7B | — | ||
| Q2 25 | $2.5B | $1.8B | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.4B | $1.7B | ||
| Q1 24 | $2.2B | — |
| Q4 25 | $-103.0M | — | ||
| Q3 25 | $179.0M | — | ||
| Q2 25 | $148.0M | $313.0M | ||
| Q1 25 | $-58.0M | — | ||
| Q4 24 | $98.0M | — | ||
| Q3 24 | $-85.0M | — | ||
| Q2 24 | $10.0M | $841.0M | ||
| Q1 24 | $-64.0M | — |
| Q4 25 | 17.0% | — | ||
| Q3 25 | 23.1% | — | ||
| Q2 25 | 17.5% | 24.4% | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | 21.8% | — | ||
| Q3 24 | 12.7% | — | ||
| Q2 24 | 16.2% | 23.9% | ||
| Q1 24 | 13.1% | — |
| Q4 25 | -3.7% | — | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | 5.8% | 17.5% | ||
| Q1 25 | -2.6% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | -3.4% | — | ||
| Q2 24 | 0.4% | 48.3% | ||
| Q1 24 | -3.0% | — |
| Q4 25 | $-0.30 | — | ||
| Q3 25 | $0.48 | — | ||
| Q2 25 | $0.40 | $0.69 | ||
| Q1 25 | $-0.16 | — | ||
| Q4 24 | $0.24 | — | ||
| Q3 24 | $-0.23 | — | ||
| Q2 24 | $0.03 | $1.86 | ||
| Q1 24 | $-0.17 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $664.0M |
| Total DebtLower is stronger | $20.8B | — |
| Stockholders' EquityBook value | $-554.0M | $12.6B |
| Total Assets | $26.4B | $18.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.7B | $664.0M | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $719.0M | — | ||
| Q2 24 | $595.0M | $1.7B | ||
| Q1 24 | $733.0M | — |
| Q4 25 | $20.8B | — | ||
| Q3 25 | $21.0B | — | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | — | ||
| Q3 24 | $21.5B | — | ||
| Q2 24 | $21.7B | — | ||
| Q1 24 | $22.1B | — |
| Q4 25 | $-554.0M | — | ||
| Q3 25 | $-565.0M | — | ||
| Q2 25 | $-764.0M | $12.6B | ||
| Q1 25 | $-1.2B | — | ||
| Q4 24 | $-1.3B | — | ||
| Q3 24 | $-1.2B | — | ||
| Q2 24 | $-1.2B | $11.6B | ||
| Q1 24 | $-1.1B | — |
| Q4 25 | $26.4B | — | ||
| Q3 25 | $26.8B | — | ||
| Q2 25 | $27.3B | $18.0B | ||
| Q1 25 | $26.4B | — | ||
| Q4 24 | $26.5B | — | ||
| Q3 24 | $26.5B | — | ||
| Q2 24 | $26.5B | $18.4B | ||
| Q1 24 | $26.9B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $746.0M |
| Free Cash FlowOCF − Capex | $403.0M | — |
| FCF MarginFCF / Revenue | 14.4% | — |
| Capex IntensityCapex / Revenue | 3.3% | — |
| Cash ConversionOCF / Net Profit | — | 2.38× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | — | ||
| Q3 25 | $405.0M | — | ||
| Q2 25 | $289.0M | $746.0M | ||
| Q1 25 | $211.0M | — | ||
| Q4 24 | $601.0M | — | ||
| Q3 24 | $405.0M | — | ||
| Q2 24 | $380.0M | $705.0M | ||
| Q1 24 | $211.0M | — |
| Q4 25 | $403.0M | — | ||
| Q3 25 | $314.0M | — | ||
| Q2 25 | $190.0M | — | ||
| Q1 25 | $96.0M | — | ||
| Q4 24 | $495.0M | — | ||
| Q3 24 | $334.0M | — | ||
| Q2 24 | $302.0M | — | ||
| Q1 24 | $129.0M | — |
| Q4 25 | 14.4% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 7.5% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 19.3% | — | ||
| Q3 24 | 13.3% | — | ||
| Q2 24 | 12.6% | — | ||
| Q1 24 | 6.0% | — |
| Q4 25 | 3.3% | — | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 3.9% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.26× | — | ||
| Q2 25 | 1.95× | 2.38× | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.13× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 38.00× | 0.84× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
TRI
Segment breakdown not available.
